We’ve made some changes to improve our site’s navigation.

Learn More

Gilead Sciences IncGILD:NSQ

50.60
1.34 / 2.58%
6.41m
99.49%
0.5012
Close in USDToday's changeShares traded1 year changeBeta
As of Jun 19 2013 21:00 BST.Data delayed by at least 15 minutes.

Consensus recommendation

As of Jun 14, 2013, the consensus forecast amongst 29 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy13
Outperform12
Hold4
Underperform0
Sell0
No opinion0

Research Reports

Datamonitor
70 pages, 18 Jun 2013
S&P Capital IQ – STARS Reports
10 pages, 15 Jun 2013
Reuters Investment Profile
12 pages, 15 Jun 2013
Directors Deals Ltd.
1 page, 06 Jun 2013

Share price forecast

The 24 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 65.00, with a high estimate of 88.00 and a low estimate of 40.00. The median estimate represents a 25.14% increase from the last price of 51.94. View Full Financials

High+73.9 %88.00
Med+28.5 %65.00
Low-20.9 %40.00

Dividends

Dividend information is not available for Gilead Sciences Inc. View Full Financials

Earnings history & estimates

On May 02, 2013, Gilead Sciences, Inc. reported 1st quarter 2013 earnings of 0.48 per share. This result was in line with the consensus of the 23 analysts following the companyand exceeded last year's 1st quarter results by 5.49%.
The next earnings announcement is expected on Jul 22, 2013. View Full Interim Financials

Average growth rate+1.45%

Gilead Sciences, Inc. reported annual 2012 earnings of 1.95 per share on Feb 04, 2013. View Full Annual Financials

Average growth rate+18.35%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

Gilead Sciences Inc. had 1st quarter 2013 revenues of 2.532bn. This missed the 2.584bn consensus estimate of the 23 analysts following the company. This was 2.19% below the prior year's 1st quarter results. View Full Interim Financials

Average growth rate+2.69%

Gilead Sciences Inc. had revenues for the full year 2012 of 9.703bn. This was 15.71% above the prior year's results. View Full Annual Financials

Average growth rate+16.49%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.



VIDEOS